• 2020 GAPNA Pharmacology Conference: Contemporary Pharmacology and Prescribing in Older AdultsJoin us at the 2020 GAPNA Pharmacology Conference:
    Contemporary Pharmacology and Prescribing in Older Adults

    April 14-18, 2020, Honolulu, HI.

    Earn up to 18 CNE hours.

     

    Find out more about it and REGISTER today!

  • AwardNew for GAPNA members: MCM Education

    GAPNA has partnered with a MCM Education to offer an ongoing series of CNE programs available to GAPNA members. "Diagnosing and Managing Parkinson’s Disease in Older Adults," is the latest program offered.

    Parkinson’s disease (PD) is characterized by both motor and nonmotor symptoms. It is diagnosed based on the presence of two of four motor symptoms including rest tremor, bradykinesia, rigidity, and gait imbalance...

    Find out about it!

  • ConventionCALL FOR: Podium and Poster Abstracts

    For the 38th GAPNA Annual Conference
    at the Hyatt Regency
    New Orleans, LA, September 24-26, 2020

    GAPNA members are invited to submit an abstract about their innovative work, that should enrich the APRN's knowledge and/or enhance the care of an older adult.

    Find out more info and deadline dates

  • Poster PresentationONLINE NOW:

    2019 GAPNA Conference Poster Presentations

    Note the latest trends in the care, education, and research of the older adult population.

     

    View the 2019 Poster Presentations from the Annual Conference!

Current Corprate Partners

GAPNA is a name chosen to reflect the diversity of our current and potential members, all who are interested in providing the highest quality of care to older adults.

We are the only advanced practice nursing organization that focuses on older adults, the fastest growing segment of the population.

View complete details about the GAPNA Corporate Partner Program.

If you would like to discuss your involvement and more details, please contact Jack Edelman, Director of Marketing, at 856-256-2313, Jack.Edelman@ajj.com or Samantha Healy, Marketing Coordinator, at 856-256-2342, samantha.healy@ajj.com.

GAPNA thanks our current Corporate Members for their support of our organization.

  

AvanirAvanir

Avanir Pharmaceuticals is a pharmaceutical company focused on bringing innovative medicines to patients with central nervous system disorders of high unmet medical need.

Corporate Headquarters
30 Enterprise, Suite 400
Aliso Viejo, CA 92656
Phone: 949-3889-6700


NeurocrineNeurocrine

Neurocrine Biosciences is a neuroscience-focused, biopharmaceutical company with more than 25 years of experience discovering and developing life-changing treatments for people with serious, challenging and under-addressed neurological, endocrine and psychiatric disorders.

The company’s diverse portfolio includes FDA-approved treatments for tardive dyskinesia and endometriosis* and clinical development programs in multiple therapeutic areas including Parkinson’s disease, congenital adrenal hyperplasia and uterine fibroids*.

Headquartered in San Diego, Neurocrine Biosciences specializes in targeting and interrupting disease-causing mechanisms involving the interconnected pathways of the nervous and endocrine systems. For more information, visit neurocrine.com, and follow the company on LinkedIn. (*in collaboration with AbbVie).

Corporate Headquarters
Neurocrine Biosciences, Inc.
12780 El Camino Real
San Diego, CA 92130
Phone: 1-858-617-7600
For more information, visit neurocrine.com, and follow the company on LinkedIn. (*in collaboration with AbbVie)


SK Life ScienceSK Life Science

SK Life Science, Inc., a subsidiary of SK Biopharmaceuticals, Co., Ltd., is focused on developing and commercializing treatments for disorders of the central nervous system (CNS). Both are a part of the global conglomerate SK Group, the second largest company in Korea. SK life science is located in Paramus, New Jersey.

We have a pipeline of eight compounds in development for the treatment of CNS disorders including epilepsy, Lennox‐Gastaux syndrome and attention deficit hyperactivity disorder, among others. The first product the company is planning to commercialize independently is cenobamate (YKP3089), an investigational compound for the potential treatment of partial‐onset seizures in adult patients.

For more information, visit their websites listed below.

SK Life Science
461 From Road, 5th Floor
Paramus, NJ 07652
Websites: SK life scienceSK Biopharmaceuticals.